Of course, myeloid and lymphoid neoplasia are different diseases, but long-term administration of JAK/STAT inhibitors may be located at a crossroads to complicate lymphoma in a patient with chronic myeloproliferative disease. Here, SOAT1 is linked to myeloproliferative neoplasm.